Rudolfomycin
Rudolfomycin is an anthracycline Antibiotic, composed of the aglycone ε-pyrromycinone and three glycosyl sugar units. Rudolfomycin inhibits the growth of mammalian tumors and exhibits antibacterial activity against Gram-positive bacteria. Rudolfomycin can be used in the research of leukemia and Gram-positive bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 69245-38-1
- Formula: C42H52N2O16
- Molecular Weight:840.87
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Description
In Vitro
Rudolfomycin (0.25-8 μg/mL) potently inhibits the growth of gram-positive bacteria including Streptococcus pneumoniae A-9585 (MIC 0.25 μg/mL), Streptococcus pyogenes A-9604 (MIC 0.5 μg/mL), Staphylococcus aureus A-9537 (MIC 2 μg/mL), Staphylococcus aureus A-9606 (MIC 8 μg/mL), and Streptococcus faecalis A-20688 (MIC 4 μg/mL), but is inactive against gram-negative bacteria and most tested fungi[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BDF1 mice (female; implanted i.p. with 106 L-1210 leukemia ascites cells)[1]
-
Dosage:12.8, 6.4, 3.2, 1.6, 0.8, 0.4 mg/kg
6.4, 3.2, 1.6, 0.8, 0.4, 0.2 mg/kg
3.2, 1.6, 0.8, 0.4, 0.2, 0.1 mg/kg
1.6, 0.8, 0.4, 0.2, 0.1, 0.05 mg/kg -
Administration:i.p.; single dose
i.p.; days 1, 4, 7
i.p.; daily, 5 days
i.p.; daily, 9 days -
Result:Attained the peak median survival time (MST) of 10.0 days and maximal % T/C value of 143 across single intraperitoneal (i.p.) bolus, intermittent day 1/4/7 i.p., 5-day daily i.p. and 9-day daily i.p. schedules at corresponding medium dose groups.
Attained a secondary MST of 9.5 days with a % T/C of 136 only in the day 1/4/7 intermittent i.p. group treated with 0.8 mg/kg.
Attained a consistent MST of 9.0 days and % T/C of 129 at multiple dosages covering all four administration modes.
Attained a uniform MST of 8.0 days and % T/C of 114 across low-dose cohorts of all four dosing regimens.
Attained a moderate MST of 7.5 days with a % T/C of 107 in the 9-day daily i.p. group at 1.6 and 0.1 mg/kg.
Attained the lowest MST of 7.0 days with a % T/C of 100 under day 1/4/7 intermittent i.p. administration at 3.2 mg/kg.
Chemical Information
-
CAS No. 69245-38-1
-
Molecular Weight 840.87
-
Formula C42H52N2O16
-
SMILES
O=C(C1[C@@](O)(CC)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4C(N)=CC([C@@H](C)O4)=O)[C@H](C)O3)[C@H](C)O2)C5=C(O)C6=C(C(C7=C(O)C=CC(O)=C7C6=O)=O)C=C15)OC
-
Structure Classification
-
Initial Source
Actinosporangium species ATCC 31127
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rudolfomycin Related Classifications
HY-126731 Related Classifications
Powered by Bioz
Keywords